Lisata Therapeutics, Inc. completed its acquisition of Marea Therapeutics, Inc. on 2026-09-17, according to the Form 8-K Lisata Therapeutics, Inc. filed with the SEC on 2026-09-17. The filing states a price of $225 million.
| Acquirer | Lisata Therapeutics, Inc. |
|---|---|
| Acquired | Marea Therapeutics, Inc. |
| Completed | 2026-09-17 |
| Price stated in the filing | $225 million |
| Reported by | Lisata Therapeutics, Inc. (LSTA), the buyer |
| Filing | Form 8-K, filed 2026-09-17 |
Want the whole picture on Lisata Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lisata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lisata Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 17, 2026, the Company completed its acquisition of Marea pursuant to the Merger Agreement.
The price, in the filing's words
Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 150,867.995 shares of Series C Preferred Stock (the "PIPE Securities") for an aggregate purchase price of approximately $225 million (the "Financing").
More from the filing
- Completion of Acquisition or Disposition of Assets.
Agreement and Plan of Merger On September 17, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the " Company" or "Lisata"), acquired Marea Therapeutics, Inc., a Delaware corporation ("Marea"), in accordance with the terms of the Agreement and Plan of Merger, dated September 17, 2026 (the "Merger Agreement"), by and among the Company, Mariner Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (" First Merger Sub"), Mariner Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), and Ma
Pursuant to the Merger Agreement, First Merger Sub merged with and into Marea, pursuant to which Marea was the surviving corporation and became a wholly owned subsidiary of the Company (the "First Merger").
Quoted from Lisata Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Lisata Therapeutics, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Lisata Therapeutics, Inc.Look up Lisata Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.